News
The day at a glance · 4 min read
Mood · Cautious
+15
Sentiment, −100 to +100
Boehringer obesity drug weight loss
16.6%
Big Pharma & Biotech
Eli Lilly PT (Barclays)
$1,350
Big Pharma & Biotech
UnitedHealth Q1 Revenue
$111.7B+2%
Managed Care & Health Insurance
Key driverRegulatory uncertainty around Amgen's Tavneos withdrawal proposal offset by competitive obesity drug developments and solid managed care earnings
Daily briefHealthcare· Money365.Market AI ·

FDA Proposes Tavneos Withdrawal; Obesity Rivalry Intensifies

Amgen faces regulatory setback while Boehringer-Zealand reports strong late-stage weight loss data. UnitedHealth beats Q1 estimates.

Big Pharma & Biotech

Neutral
AMGNLLYABBVRLAYPFE
Amgen ($AMGN) faces regulatory pressure as the FDA's Center for Drug Evaluation and Research has proposed withdrawal of Tavneos from the US market, marking a significant setback for the company's rare disease portfolio. In the competitive obesity space, Boehringer Ingelheim's experimental drug demonstrated average weight loss of up to 16.6% in a late-stage trial, intensifying competition with established players.
Eli Lilly ($LLY) continues to draw analyst attention despite recent script disappointments for its weight loss franchise, with Barclays maintaining an Overweight rating and $1,350 price target following the Kelonia acquisition.
AbbVie ($ABBV) reported positive head-to-head data for $ABBV's RINVOQ (upadacitinib), which demonstrated superiority versus HUMIRA (adalimumab) for the primary endpoint of achieving low disease activity at week 12 in rheumatoid arthritis patients who failed their first TNF inhibitor in the SELECT-SWITCH study.
Relay Therapeutics ($RLAY) unveiled new triplet regimen data for zovegalisib in heavily pretreated metastatic breast cancer patients and signed a supply deal with Pfizer ($PFE) to support Phase III development plans.

Managed Care & Health Insurance

Bullish

UnitedHealth Fair Value (updated)

$386.08

UnitedHealth Fair Value (prior)

$364.63
UNH
UnitedHealth Group ($UNH) delivered a strong first quarter performance, reporting revenue of $111.7 billion, up 2% year-over-year and exceeding Wall Street estimates of $109.6 billion. The company also beat earnings expectations, demonstrating resilience amid ongoing regulatory and margin pressures across the managed care sector. Analysts have updated their fair value estimate for $UNH to $386.08 compared with the prior $364.63, though the revised valuation reflects mixed views on regulation, margins, and pricing risks. The stock's recent performance shows caution, with shares down approximately 6% over the past month despite the positive earnings beat.

MedTech & Devices

Bullish
ISRGJNJ
Intuitive Surgical ($ISRG) screens as a strong growth stock with promising technical setup near resistance levels, signaling potential breakout opportunities for investors according to technical analysis. The surgical robotics leader continues to demonstrate strong financial health and growth characteristics.
Johnson & Johnson ($JNJ) expanded its cardiovascular portfolio by entering a definitive agreement to acquire Atraverse Medical, a developer of next-generation cardiac ablation technology centered on the FDA-cleared Hotwire left-heart access system used in cardiac ablation procedures. The deal targets expansion in atrial fibrillation and cardiac rhythm management, aligning with $JNJ's strategic focus despite recent share price weakness of approximately 6% over the past month.

FDA & Regulation

Bearish
AMGNGILD
The FDA's proposal to withdraw Amgen's ($AMGN) Tavneos represents a significant regulatory development that could impact treatment options for rare disease patients. The action by the Center for Drug Evaluation and Research underscores heightened regulatory scrutiny across the pharmaceutical sector.
Gilead Sciences ($GILD) faces shareholder pressure as AHF filed a shareholder resolution seeking greater transparency on patent exclusivities, reflecting ongoing tensions around drug pricing and intellectual property strategies. The regulatory landscape continues to evolve with increasing focus on market access, reimbursement challenges, and patent practices across the industry.

Biotech Equity Performance

Neutral

Moderna share price

$48.69

Moderna YTD performance

+57.8%

Moderna 1-year performance

+77.3%
MRNA
Moderna ($MRNA) closed at $48.69 with volatility across multiple timeframes, declining 10.8% over the past seven days and 1.8% over 30 days, while showing gains of 57.8% year-to-date and 77.3% over the past year. The stock's longer-term performance remains challenged with three-year and five-year returns showing declines of 63.5% and 73.8% respectively, as investors continue to assess the company's valuation and growth trajectory beyond its COVID-19 franchise. Analyst commentary frames $MRNA as a key biotech name with ongoing questions about whether current pricing reflects true value or if the market is still determining appropriate valuation levels.

Looking Ahead

Neutral
LLYRLAYPFE
The healthcare sector faces multiple catalysts in coming weeks including Eli Lilly's ($LLY) upcoming earnings report, which commentators expect will address recent weight loss drug script concerns and tell a positive story despite controversy.
Relay Therapeutics continues advancing its Phase III planning for zovegalisib with Pfizer supply support, while the ESR1 mutated metastatic breast cancer market evolves rapidly with increasing adoption of liquid biopsies and next-generation sequencing for earlier detection. Market research indicates expanding opportunities across multiple therapeutic areas including HPV-related cancers, pancreatic neuroendocrine tumors, and gastroesophageal adenocarcinoma, with leading companies advancing innovative treatment approaches despite reimbursement and cost challenges.

Important Disclaimer — Not Investment Advice

Disclaimer: This article is provided by Money365.Market for general information and educational purposes only. It is not financial advice, a personal recommendation, or an inducement to buy, sell, or invest in any security or product. Capital is at risk and the value of investments can go down as well as up; past performance does not indicate future results. You should seek independent advice from an FCA-authorised adviser before making any financial decision.

Read the full disclaimer — 8 further points, including total-loss risk, our regulatory status and conflicts of interest

Nothing here is an offer or a solicitation to buy or sell anything, and reading it creates no advisory or fiduciary relationship between you and Money365.Market. Any decision you take is your own.

  • You can lose money — including all of it. Individual companies can and do fail, and some of the assets discussed can fall to zero. Only commit money you can afford to lose, and never borrow to invest on the strength of anything you read here.
  • Forecasts are opinion, not fact. Any valuation model, scenario, fair-value range, estimate or other forward-looking statement is illustrative, rests on assumptions that may prove wrong, and is never a price target, a forecast of actual outcomes, or a promise of any return.
  • Published at a point in time. Figures were believed accurate on the publication or last-updated date shown above and are not maintained afterwards; we are under no obligation to update them. Market and company data comes from third-party sources and is provided without warranty of accuracy, completeness or timeliness.
  • Automated content. This brief was compiled by an automated pipeline from validated news and market-data sources and passed through editorial and compliance checks. Automated content can still contain errors — verify anything you intend to rely on.
  • We are not regulated. Money365.Market is not authorised or regulated by the UK Financial Conduct Authority, is not registered with the U.S. Securities and Exchange Commission or FINRA as an investment adviser or broker-dealer, and is not a tax adviser. We hold no licence to give personal financial advice and do not do so.
  • Interests and independence. Money365.Market is not affiliated with, endorsed by or sponsored by any company, fund, exchange or platform mentioned, and is not paid to feature them. The author may hold positions in securities or assets discussed. The site earns revenue from advertising, subscriptions and, where labelled, affiliate links; this does not influence what we publish.
  • Your jurisdiction matters. Tax treatment, contribution limits, product availability and investor protections differ by country and can change. Speak to a qualified tax professional for tax matters, and to a locally licensed adviser if you are outside the UK.

Full terms: Disclaimer · Terms of Service · Privacy Policy